Dr. Yardley on Challenges With Resistance Mechanisms in HR+/HER2- Breast Cancer

Video

In Partnership With:

Denise Yardley, MD, discusses challenges with ​resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer. 

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses challenges with ​resistance mechanisms in hormone receptor (HR)–positive, HER2-negative breast cancer. 

​Resistance to CDK4/6 inhibitors remains a significant challenge in HR-positive, HER2-negative breast cancer, says Yardley. Learning how to characterize and predict resistance early on is of critical importance. 

Notably, several ongoing studies are trying to identify sensitivity and resistance biomarkers, ​Yardley says. However, estrogen receptor positivity remains the most established biomarker for benefit. 

In addition, the field is looking for ways to identify patients who may have intrinsic resistance, ​resistance after 6 months, or acquired resistance through Rb, PI3K, and cyclin E, Yardley concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD